ReviewJournal of cardiovascular pharmacology2020
Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).
Review in Journal of cardiovascular pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 60 citations in OpenAlex.
- Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease.Natural products and bioprospecting · 2024Review
- Routine statins use is associated with less adverse outcome in patients above 70 years of age admitted to hospital with COVID-19.BMC geriatrics · 2023Article
- Autoimmune Pulmonary Alveolar Proteinosis That Improved after a COVID-19 Episode.Internal medicine (Tokyo, Japan) · 2023Article
- The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review.Inflammopharmacology · 2022Review
- The Potential Impact of COVID-19 Virus on the Heart and the Circulatory System.Infection and drug resistance · 2022Review
- Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease.Expert opinion on pharmacotherapy · 2021Review
- COVID-19: The Impact on Cardiovascular System.Biomedicines · 2021Review
- Do interferons play a role in COVID-19?International journal of clinical practice · 2021Article
- Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.Cardiovascular drugs and therapy · 2021Review
- Considerations When Managing Heart Failure during the COVID-19 Pandemic-Consensus from the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2021Review
- COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.Rheumatology international · 2021Review
- COVID-19 and Cardiovascular Diseases.Advances in experimental medicine and biology · 2021Article
- Cardiovascular Complications in Major 21st Century Viral Epidemics and Pandemics: an Insight into COVID-19.Current cardiology reviews · 2021Review
- Fabry disease and COVID-19: international expert recommendations for management based on real-world experience.Clinical kidney journal · 2020Article
- COVID-19-Related Cardiovascular Disease and Practical Considerations for Perioperative Clinicians.Seminars in cardiothoracic and vascular anesthesia · 2020Review
- Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury.International journal of molecular sciences · 2020Review
- Cardiology on the cutting edge: updates from the European Society of Cardiology (ESC) Congress 2020.BMC cardiovascular disorders · 2020Article
- Willingness to comply with physical distancing measures against COVID-19 in four African countries.BMJ global health · 2020Article
- Is Sex a Determinant of COVID-19 Infection? Truth or Myth?Current hypertension reports · 2020Review
- Risk of peripheral arterial thrombosis in COVID-19.Journal of vascular surgery · 2020Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequelae, such as myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.